第8版AJCC肝内胆管癌TNM分期的解读与验证

doi:10.16139/j.1007-9610.2018.03.009

外科理论与实践 ›› 2018, Vol. 23 ›› Issue (03): 221-226.doi: 10.16139/j.1007-9610.2018.03.009

第8版AJCC肝内胆管癌TNM分期的解读与验证

施杰毅, 高强, 周俭, 樊嘉

复旦大学附属中山医院肝外科,复旦大学肝癌研究所,上海 200032

收稿日期:2018-02-01 发布日期:2020-07-25
通讯作者: 高强,E-mail: gao.qiang@zs-hospital.sh.cn
基金资助:
国家自然科学基金（81572292,81522036）; 国家万人计划青年拔尖人才计划(W02070061); 上海市教委曙光计划; 上海市卫生系统优秀学科带头人计划(2017BR002)

Received:2018-02-01 Published:2020-07-25

摘要/Abstract

中图分类号:

R735.7

施杰毅, 高强, 周俭, 樊嘉. 第8版AJCC肝内胆管癌TNM分期的解读与验证[J]. 外科理论与实践, 2018, 23(03): 221-226.

[1] Aljiffry M, Abdulelah A, Walsh M, et al.Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature[J]. J Am Coll Surg,2009,208(1):134-147.
[2] Poultsides GA, Zhu AX, Choti MA, et al.Intrahepatic cholangiocarcinoma[J]. Surg Clin North Am,2010,90(4):817-837.
[3] Lin XH, Luo JC.The risk factors and prognostic factors of intrahepatic cholangiocarcinoma[J]. J Chin Med Assoc,2017,80(3):121-122.
[4] Nakano M, Ariizumi SI, Yamamoto M.Intrahepatic cholangiocarcinoma[J]. Semin Diagn Pathol,2017,34(2):160-166.
[5] Spolverato G, Ejaz A, Kim Y, et al.Tumor size predicts vascular invasion and histologic grade among patients undergoing resection of intrahepatic cholangiocarcinoma[J]. J Gastrointest Surg,2014,18(7):1284-1291.
[6] Spolverato G, Kim Y, Ejaz A, et al.Conditional probabi-lity of long-term survival after liver resection for intrahe-patic cholangiocarcinoma: a multi-institutional analysis of 535 patients[J]. JAMA surgery,2015,150(6):538-545.
[7] Doussot A, Groot-Koerkamp B, Wiggers JK, et al.Outcomes after resection of intrahepatic cholangiocarcinoma: external validation and comparison of prognostic models[J]. J Am Coll Surg,2015,221(2):452-461.
[8] Edge SB, Compton CC.The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol,2010, 17(6):1471-1474.
[9] Nathan H, Aloia TA, Vauthey JN, et al.A proposed sta-ging system for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol,2009,16(1):14-22.
[10] de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahe-patic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment[J]. J Clin Oncol,2011,29(23):3140-3145.
[11] Farges O, Fuks D, Le Treut YP, et al.AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group[J]. Cancer,2011, 117(10):2170-2177.
[12] Igami T, Ebata T, Yokoyama Y, et al.Staging of peri-pheral-type intrahepatic cholangiocarcinoma: appraisal of the new TNM classification and its modifications[J]. World J Surg,2011,35(11):2501-2509.
[13] Spolverato G, Vitale A, Cucchetti A, et al.Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?[J]. Cancer,2015,121(22):3998-4006.
[14] Si A, Li J, Xiang H, et al.Actual over 10-year survival after liver resection for patients with intrahepatic cholangiocarcinoma[J]. Oncotarget,2017,8(27):44521-44532.
[15] Kang SH, Hwang S, Lee YJ, et al.Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci,2018,25(4):240-248.
[16] Uno M, Shimada K, Yamamoto Y, et al.Periductal infiltrating type of intrahepatic cholangiocarcinoma: a rare macroscopic type without any apparent mass[J]. Surg Today,2012,42(12):1189-1194.
[17] Guglielmi A, Ruzzenente A, Campagnaro T, et al.Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection[J]. World J Surg,2009,33(6):1247-1254.

第8版AJCC肝内胆管癌TNM分期的解读与验证

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	尹彦江, 罗治文, 陈晓, 张业繁, 黄振, 赵宏, 赵建军, 李智宇, 周健国, 蔡建强, 毕新宇. 肝内胆管癌病人肝脏手术切缘与预后的关系[J]. 外科理论与实践, 2022, 27(3): 221-228.
[2]	周易, 陈影, 陈尔真. 甲状腺激素对脓毒症脏器功能维护作用的研究进展[J]. 内科理论与实践, 2022, 17(05): 408-412.
[3]	杨崔燕, 王豪雨, 陈小松, 沈坤炜. 抑癌基因TP53突变状态与三阴性乳腺癌病人预后的研究[J]. 外科理论与实践, 2022, 27(05): 421-428.
[4]	张吉祥, 谢智华, 综述, 李炜, 姜小清, 审校. 肝内胆管癌的分型和外科治疗热点[J]. 外科理论与实践, 2022, 27(05): 478-482.
[5]	徐娜娜, 吴涛, 寇明坤, 白海. ASXL1基因突变在急性髓系白血病中的研究进展[J]. 内科理论与实践, 2022, 17(04): 353-355.
[6]	程威, 黄雨桦, 王剑, 李幼生. 影响癌性肠梗阻病人预后的多因素分析[J]. 外科理论与实践, 2022, 27(04): 340-345.
[7]	陈敏, 车在前, 陈影, 马丽, 赵冰, 周伟君, 毛恩强, 陈尔真. 白细胞血小板比值早期评估脓毒症预后的临床研究[J]. 内科理论与实践, 2022, 17(03): 208-213.
[8]	李蕾, 袁菲, 王朝夫, 许海敏, 王婷. 101例壶腹部腺癌临床病理及预后因素分析[J]. 诊断学理论与实践, 2022, 21(03): 355-361.
[9]	刘深洋, 汤朝晖, 全志伟. 肝内胆管癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 100-106.
[10]	方诚, 夏勇, 王葵, 沈锋. 肝内胆管癌转化治疗现状与展望[J]. 外科理论与实践, 2022, 27(02): 107-112.
[11]	沐阳, 陈欣. 血浆降钙素原和C反应蛋白对多发伤病人预后评估的价值[J]. 外科理论与实践, 2021, 26(6): 532-536.
[12]	符国新王舒舒何垚宋晓萌朱载瓯. 腮腺手术中应用美容切口与 Blair 切口比较的系统评价及 Meta 分析 [J]. 组织工程与重建外科杂志, 2021, 17(6): 532-.
[13]	陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528.
[14]	冯国伟, 张晓娟, 郭睿, 关哲, 王越. 治疗前¹⁸F-FDG PET/CT显像对结外NK/T细胞淋巴瘤的预后判断价值[J]. 诊断学理论与实践, 2021, 20(06): 533-539.
[15]	梁亚丽, 赵海港, 项广宇. 应激性高血糖比值预测急性缺血性脑卒中患者溶栓治疗后1年不良预后的价值[J]. 诊断学理论与实践, 2021, 20(06): 562-566.